Spots Global Cancer Trial Database for Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Official Title: An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations
Study ID: NCT01026415
Study Description
Brief Summary: The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle, Washington, United States
Contact Details
Name: Thomas Manley, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
